Key result
Therapeutic thoracic irradiation (30-40 Gy) is associated with a 2- to >7-fold increased risk of cardiac death in long-term cancer survivors, with risk increasing linearly with dose.
Why the study?
What are the mechanisms and dose-response relationships for radiation-induced cardiovascular disease?
What are the mechanisms and dose-response relationships for radiation-induced cardiovascular disease?
Effect estimate: 2- to >7-fold increase in risk
Therapeutic thoracic irradiation significantly increases the risk of cardiovascular disease and cardiac death through dose-dependent mechanisms involving endothelial inflammation, microvascular loss, and accelerated atherosclerosis.
Supports cardiac dose minimization in thoracic RT; leaves open prospective validation of linear risk models in modern regimens.
Epidemiological studies have shown a clear association between therapeutic doses of thoracic irradiation and increased risk of cardiovascular disease in long-term cancer survivors. Survivors of Hodgkin's lymphoma and childhood cancers, for example, show 2- to >7-fold increases in risk of cardiac death after total tumour doses of 30-40 Gy, given in 2-Gy fractions. The risk of cardiac mortality increases linearly with dose, although there are large uncertainties for mean cardiac doses <5 Gy. Experimental studies show that doses of ≥ 2 Gy induce the expression of inflammatory and thrombotic molecules in endothelial cells. In the heart, this causes progressive loss of capillaries and eventually leads to reduced perfusion, myocardial cell death, and fibrosis. In large arteries, doses of ≥ 8 Gy, combined with elevated cholesterol, initiates atherosclerosis and predisposes to the formation of inflammatory, unstable lesions, which are prone to rupture and may cause a fatal heart attack or stroke. In contrast, doses <1 Gy inhibit inflammatory cell adhesion to endothelial cells and inhibit the development of atherosclerosis in mice. It seems likely that mechanisms other than accelerated atherosclerosis are responsible for cardiovascular effects after low total-body exposures of radiation (e.g. impaired T-cell immunity or persistent increase in systemic cytokines).
No takes yet. Share an insight, caveat, or question.
Fiona Stewart (2012) conducted a review in Cancer survivors (Hodgkin's lymphoma and childhood cancers). Thoracic irradiation was evaluated on Cardiac death (2- to >7-fold increase in risk). Therapeutic thoracic irradiation (30-40 Gy) is associated with a 2- to >7-fold increased risk of cardiac death in long-term cancer survivors, with risk increasing linearly with dose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: